SEC Filing Summary: Health Sciences Acquisitions Corporation 2 (HSAC2)
Business Context and Reporting Period
This Form 8-K was filed on January 19, 2023, by Health Sciences Acquisitions Corporation 2 (HSAC2), a Cayman Islands exempted company. The filing addresses a notice of delisting received from The Nasdaq Stock Market due to a failure to hold an annual meeting of stockholders within 12 months of the fiscal year ended December 31, 2021. The company is currently in the process of a business combination with Orchestra BioMed, Inc.
Key Financial Metrics
The filing text does not provide specific financial data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. This report focuses exclusively on corporate governance and listing status.
Material Changes and Events
- Nasdaq Delisting Notice: HSAC2 received notice of failure to comply with Nasdaq Listing Rule 5620(a) regarding the annual meeting requirement.
- Compliance Timeline: The company has 45 calendar days (until March 5, 2023) to submit a compliance plan. If accepted, Nasdaq may grant up to 180 days (until June 29, 2023) to regain compliance.
- Strategic Response: HSAC2 does not intend to submit a compliance plan. Instead, it plans to consummate the business combination with Orchestra BioMed, Inc. to be treated as a newly-listed company.
- Upcoming Vote: An extraordinary general meeting of shareholders is scheduled for January 24, 2023, to vote on the business combination.
Outlook, Risks, and Management Commentary
Management believes that upon consummation of the business combination, the combined entity will be treated as a newly-listed company. Under this status, the requirement to hold an annual meeting would reset to within one year after the first fiscal year end following the new listing (potentially until December 31, 2024). The filing includes standard forward-looking statement disclaimers regarding the ability to complete the business combination, potential delisting risks, and future liquidity.
Key Facts for Investor Verification
- Verify the outcome of the extraordinary general meeting scheduled for January 24, 2023, regarding the Orchestra BioMed business combination.
- Confirm whether the business combination is consummated before the March 5, 2023, deadline for submitting a Nasdaq compliance plan.
- Monitor Nasdaq's official listing status for HSAC2 (trading symbol: HSAQ) to ensure the stock remains tradable pending the merger.
- Review the proxy statement/prospectus dated December 16, 2022, for detailed terms of the proposed merger.